Navigation Links
American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer
Date:6/9/2008

- Anindya Chatterjee Brings Over Thirteen Years of Capital Markets

Experience to AOBO - - New Role Emphasizes Strategic Growth Plan and Capital Markets Interaction

-

NEW YORK, June 9 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) ("AOB" or "the Company"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced the appointment of Anindya Chatterjee to Chief Strategy Officer, effective May 23, 2008. Based in New York, Anindya Chatterjee will report to Lily Li, Chief Financial Officer, Chief Operating Officer and co-founder of the Company.

Anindya Chatterjee will work closely with AOBO's management team to shape and execute the Company's core growth initiatives, including acquisition-led expansion and capital markets strategy. Further, he will also serve as the Company's interface with the investment community, playing a crucial role in enhancing investor communications and transparency.

Anindya Chatterjee brings more than thirteen years of capital markets experience to AOBO. He was previously a Managing Director in equity research at Jefferies & Co, where he headed Emerging Asian (China & India) equity research. He was also a Strategist and Economist focused on Non-Japan Asia for Bear Stearns & Company in Hong Kong. He held similar positions at IDEA INC. in New York, and NatWest Markets in Singapore, where he was the Emerging Markets Strategist and Regional Economist and Equity Strategist, respectively. He also was the Head of Research at ANZ Investment Bank in India, and held research positions at HSBC Securities and Smith New Court Securities.

Tony Liu, AOBO's Chief Executive Officer and Chairman stated, "We are excited to add Anindya to our core management team at this crucial time of rapid business expansion. Anindya brings a deep understanding our Company, our sector and our corporate culture in addition to his invaluable capital markets experience, and long-standing credibility among global institutional investors."

Anindya Chatterjee stated, "As an equity analyst, I have interacted regularly with AOBO's investors and management team, and I am very pleased to accept this strategic role at a Company with such strong fundamental performance, exciting growth prospects, and cohesive team. With my investment research experience and knowledge of the capital markets, I look forward to enhancing and executing AOBO's key growth initiatives, including the acquisition strategy and navigating the U.S. capital markets."

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China. For more information, visit http://www.bioaobo.com.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2007, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.


'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... and commercializing products to treat rare diseases where ... the long-term follow-up data from its Phase 2 ... Defense Regulator (IDR), in the treatment of oral ... undergoing chemoradiation therapy (CRT).  The additional 12-month safety ...
(Date:12/8/2016)... Korea , Dec. 8, 2016 Eutilex ... $21 billion KRW (US $18.9M) Series A financing. This ... Investment, G.N. Tech Venture and SNU Bio Angel. This ... to 30.5 billion KRW (US $27.7M) since its founding ... Eutilex to bolster the development and commercialization of its ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... concluded that “in the setting of previously treated, advanced pancreatic cancer, liquid biopsies ... the optimal patient population and timing of blood sampling may improve the value ...
(Date:12/7/2016)... 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") announces ... at the Company,s Annual and Special Meeting. ... place on Thursday, December 15, 2016 at Mount ... EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta ... meeting and management information circular, containing the matters to be ...
Breaking Biology Technology:
(Date:11/16/2016)... Sensory Inc ., a Silicon ... consumer electronics, and VeriTran , a technology ... today announced a global partnership that will provide ... users of mobile banking and mobile payments solutions.  ... which requires no specialized biometric scanners, yet provides ...
(Date:11/14/2016)... Nov. 14, 2016  xG Technology, Inc. ("xG" or ... critical wireless communications for use in challenging operating environments, ... 30, 2016. Management will hold a conference call to ... p.m. Eastern Time (details below). Key Recent ... $16 million binding agreement to acquire Vislink Communication Systems. ...
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
Breaking Biology News(10 mins):